<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000966</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 156</org_study_id>
    <nct_id>NCT00000966</nct_id>
  </id_info>
  <brief_title>A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS</brief_title>
  <official_title>A Dose-Escalation, Phase I/II Study of Oral Azithromycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness and toxicity of oral azithromycin and pyrimethamine as acute&#xD;
      therapy for toxoplasmic encephalitis in AIDS patients. To assess the toxicity and&#xD;
      effectiveness of azithromycin alone as maintenance therapy.&#xD;
&#xD;
      Encephalitis caused by Toxoplasma gondii is the most frequent cause of focal central nervous&#xD;
      system infection in patients with AIDS. Untreated, the encephalitis is fatal. Standard&#xD;
      treatment for toxoplasmic encephalitis is associated with serious adverse effects. Thus,&#xD;
      alternative treatments are needed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Encephalitis caused by Toxoplasma gondii is the most frequent cause of focal central nervous&#xD;
      system infection in patients with AIDS. Untreated, the encephalitis is fatal. Standard&#xD;
      treatment for toxoplasmic encephalitis is associated with serious adverse effects. Thus,&#xD;
      alternative treatments are needed.&#xD;
&#xD;
      Patients with toxoplasmosis are given azithromycin at doses starting at the lowest dose for&#xD;
      the first cohort, an intermediate dose for the second cohort, and a higher dose for the third&#xD;
      cohort. Subsequent cohorts may receive azithromycin in increased dosage, if needed to&#xD;
      determine the MTD. All patients also receive pyrimethamine. Folinic acid is also provided for&#xD;
      as long as patients receive pyrimethamine. Patients are evaluated for clinical response to&#xD;
      treatment at days 3, 7, and 14, and weekly for 6 weeks. Maintenance treatment with&#xD;
      azithromycin continues for an additional 24 weeks. Patients who complete the study period&#xD;
      without relapse or significant toxicity are offered continued therapy by the drug company and&#xD;
      are followed for survival and relapse on a monthly basis for 1 year. After the MTD is&#xD;
      determined, a subsequent cohort may be added for special studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>45</enrollment>
  <condition>Toxoplasmosis, Cerebral</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrimethamine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin calcium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia (PCP).&#xD;
&#xD;
          -  Allowed during maintenance period (weeks 7 - 24):&#xD;
&#xD;
          -  Zidovudine and other antiretrovirals available through treatment IND mechanisms,&#xD;
             ganciclovir, and maintenance doses of amphotericin (other investigational therapies&#xD;
             require permission from the study chair), steroids for the treatment of acute PCP.&#xD;
&#xD;
          -  Isoniazid (INH) only for patients already on INH.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  HIV infection or belong to high-risk group. Presumptive or definite diagnosis of&#xD;
             toxoplasmic encephalitis.&#xD;
&#xD;
          -  Each patient, or his/her appropriate family member, or legal designee must be able to&#xD;
             understand and sign a written informed consent, in accordance with the local practices&#xD;
             at each site.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  History of cerebral toxoplasmosis or toxoplasmosis infection in any other organ or&#xD;
             tissue.&#xD;
&#xD;
          -  Coma.&#xD;
&#xD;
          -  More than 72 hours of treatment for current episode of toxoplasmic encephalitis prior&#xD;
             to study entry.&#xD;
&#xD;
          -  Central nervous system (CNS) lymphoma.&#xD;
&#xD;
          -  Cerebral Kaposi's sarcoma.&#xD;
&#xD;
          -  Active hepatitis or clinical jaundice.&#xD;
&#xD;
          -  History of serious hypersensitivity or intolerance to any of the study drugs.&#xD;
&#xD;
          -  Serum or cerebrospinal fluid (CSF) positive for cryptococcus antigen or culture.&#xD;
&#xD;
          -  Malignancies requiring use of cytotoxic chemotherapy.&#xD;
&#xD;
          -  Inability to take oral therapy reliably.&#xD;
&#xD;
          -  Malabsorption syndrome.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Opportunistic infection requiring either acute treatment or maintenance therapy with&#xD;
             azithromycin, erythromycin or other macrolides, sulfonamides, amphotericin, dapsone,&#xD;
             ganciclovir, antifolates, and other investigational agents except erythropoietin. For&#xD;
             first 6 weeks of treatment, patients may not receive treatment with erythromycin (or&#xD;
             other macrolides), sulfonamides, immunomodulators with the exception of alpha&#xD;
             interferon, lymphocyte replacement, cytotoxic chemotherapy, dapsone, ganciclovir,&#xD;
             rifampicin, coumadin, antiretrovirals, and investigational agents other than&#xD;
             erythropoietin.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Negative HIV antibodies by a federally licensed ELISA, unless there is documentation&#xD;
             of a previously positive HIV culture or p24 antigen.&#xD;
&#xD;
          -  Infections of the central nervous system.&#xD;
&#xD;
          -  Malignancies requiring the use of cytotoxic chemotherapy.&#xD;
&#xD;
          -  Any medical or social condition that, in the opinion of the investigator, would&#xD;
             adversely affect participation and/or compliance in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luft B</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Remington J</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles County - USC Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>331361013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Massachusetts Med Ctr</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Municipal Hosp Ctr/Jacobi Med Ctr</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Med Ctr / Bronx Municipal Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Veterans Administration / Mount Sinai Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nassau County Med Ctr</name>
      <address>
        <city>East Meadow</city>
        <state>New York</state>
        <zip>11554</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellevue Hosp / New York Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY - Stony Brook</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>117948153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Julio Arroyo</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Saba J, Morlat P, Raffi F, Hazebroucq V, Joly V, Leport C, Vilde JL. Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. Eur J Clin Microbiol Infect Dis. 1993 Nov;12(11):853-6. doi: 10.1007/BF02000407.</citation>
    <PMID>8112357</PMID>
  </reference>
  <reference>
    <citation>. Kamarulzaman A, Hoy J. Effect of folinic acid on haematological toxicity during treatment of cerebral toxoplasmosis in patients with AIDS. Annu Conf Australas Soc HIV Med. 1995 Nov 16-19;7:68 (abstract no 68)</citation>
  </reference>
  <reference>
    <citation>Jacobson JM, Hafner R, Remington J, Farthing C, Holden-Wiltse J, Bosler EM, Harris C, Jayaweera DT, Roque C, Luft BJ; ACTG 156 Study Team. Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. AIDS. 2001 Mar 30;15(5):583-9. doi: 10.1097/00002030-200103300-00007.</citation>
    <PMID>11316995</PMID>
  </reference>
  <verification_date>October 1994</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>August 25, 2008</last_update_submitted>
  <last_update_submitted_qc>August 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2008</last_update_posted>
  <keyword>Toxoplasmosis</keyword>
  <keyword>Toxoplasma</keyword>
  <keyword>Pyrimethamine</keyword>
  <keyword>Leucovorin</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Encephalitis</keyword>
  <keyword>Administration, Oral</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Azithromycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Toxoplasmosis</mesh_term>
    <mesh_term>Toxoplasmosis, Cerebral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

